IP Law News

Vifor Pharma Sues Alkem, Ascent to Block Copies of Veltassa Drug

Jan. 24, 2020, 10:02 PM

Vifor Pharma’s Relypsa unit said proposed generic versions of a treatment for high levels of potassium in blood by Alkem and Ascent infringe as many as four patents for Veltassa.

  • Vifor is seeking court orders blocking copies until the patents have expired, according to a complaint filed Thursday in federal court in Wilmington, Delaware
  • Vifor claims Alkem infringes four patents and Ascent three
  • Two patents expire in October 2033; two others expire in June 2028 and May 2030: FDA Orange Book
  • Veltassa is a potassium binder used to treat hyperkalemia, a condition in which there is too much potassium...

To read the full article log in. To learn more about a subscription click here.